Skip to main content
Fig. 4 | Journal of Translational Medicine

Fig. 4

From: A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer

Fig. 4

pAXLxCD3ε and Olaparib combinatorial approach. A Relative % of T cell mediated cytotoxicity of ES-2 cells co-cultured at 10:1 E:T ratio in the presence of vehicle,1 μg/ml of pAXLxCD3ε and Olaparib 1 μM + pAXLxCD3ε 1 μg/ml. B % of IFN-y production in T cells co-cultured with ES-2 cells at 10:1 E:T ratio in the presence of vehicle,1 μg/ml of pAXLxCD3ε and Olaparib 1 μM + pAXLxCD3ε 1 μg/ml. Student’s t-test was applied to calculate statistical significance *p < 0.05, **p < 0.01, ***p < 0.001. p values are calculated by comparing PBMC co-cultured with ES-2 cells treated with vehicle to co-cultures of PBMC + target cells treated with pAXLxCD3ε or Olaparib or pAXLxCD3ε+ Olaparib. Relative toxicity is calculated by normalizing pAXLxCD3ε, Olaparib and pAXLxCD3ε plus Olaparib treated cells co-cultured with PBMC on negative control (co-cultures of ES-2 + PBMC exposed to vehicle) placed equally to zero

Back to article page